Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors

Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese patients with advanced solid tumors (not selected based on their MET status). The primary objective was to determine the maximum tolerated do...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Esaki, Taito, Hirai, Fumihiko, Makiyama, Akitaka, Seto, Takashi, Bando, Hideaki, Naito, Yoichi, Yoh, Kiyotaka, Ishihara, Kae, Kakizume, Tomoyuki, Natsume, Kazuto, Myers, Andrea, Doi, Toshihiko
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6447844/
https://ncbi.nlm.nih.gov/pubmed/30724423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13956
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados